Patents by Inventor Joon Won Jeong

Joon Won Jeong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE
    Publication number: 20230089073
    Abstract: Provided herein are GLP-1 receptor modulator compounds, pharmaceutical compositions, methods of their preparation, and methods of their use in treatment, and/or diagnosis.
    Type: Application
    Filed: January 27, 2022
    Publication date: March 23, 2023
    Inventors: Xiaohui DU, Ray Fucini, Xu Ran, Chien-Hung Yeh, Xiang Zhou, Rui Gao, Joon Won Jeong, Li Liu, Subas Man Sakya, Xiaofang Wang, Hiroyuki Kawai, Craig Lee, David Lloyd, Stig Hansen
  • N-cyano-7-azanorbornane derivatives and uses thereof
    Patent number: 11572374
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: February 7, 2023
    Assignee: AMGEN INC.
    Inventors: John R. Butler, Daniel Erlanson, Russell Graceffa, Jeffrey Iwig, Joon Won Jeong, Ryan D. White, Yongwei Wu, Shuyan Yi, Xiao Mei Zheng, Jesse M. McFarland, Abhisek Banerjee
  • N-CYANO-7-AZANORBORNANE DERIVATIVES AND USES THEREOF
    Publication number: 20220363694
    Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of the invention, a method for manufacturing compounds of the invention and therapeutic uses thereof.
    Type: Application
    Filed: August 13, 2019
    Publication date: November 17, 2022
    Applicants: Amgen Inc., Carmot Therapeutics, Inc.
    Inventors: John R. BUTLER, Daniel ERLANSON, Russell GRACEFFA, Jeffrey IWIG, Joon Won JEONG, Ryan D. WHITE, Yongwei WU, Shuyan YI, Xiao Mei ZHENG, Jesse M. MCFARLAND, Abhisek BANERJEE
  • KRAS G12C inhibitors and methods of using the same
    Patent number: 11053226
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: July 6, 2021
    Assignee: AMGEN INC.
    Inventors: Youngsook Shin, Victor J. Cee, Christopher M. Tegley, Brian Alan Lanman, Ryan Paul Wurz, Kevin C. Yang, Vu Van Ma, Daniel Erlanson, Joon Won Jeong, Raymond V. Fucini, Jeffrey Iwig
  • KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20200165231
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Application
    Filed: November 18, 2019
    Publication date: May 28, 2020
    Inventors: Youngsook SHIN, Victor J. CEE, Christopher M. TEGLEY, Brian Alan LANMAN, Ryan Paul WURZ, Kevin C. YANG, Vu Van MA, Daniel ERLANSON, Joon Won JEONG, Raymond V. FUCINI, Jeffrey IWIG
  • ROR? modulators
    Patent number: 10035790
    Abstract: Described are RORy modulators of the formula (I), and N-oxides thereof, and pharmaceutically acceptable salts thereof, and solvates and hydrates thereof, wherein R1, R2, R3, R4, R5, R6, Ra, x, y, L, G, Z, the bond denoted by “q”, the ring system denoted by “A” and the ring system denoted by “B” are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORy activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORy activity, for example, autoimmune and/or inflammatory disorders.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: July 31, 2018
    Assignees: Exelixis, Inc., Bristol-Myers Squibb Co.
    Inventors: Wei Xu, Yong Wang, Sunghoon Ma, Elena S. Koltun, Byung Gyu Kim, Joon Won Jeong, T. G. Murali Dhar, Lynne Canne Bannen
  • RORGamma Modulators
    Publication number: 20150266856
    Abstract: Described are RORy modulators of the formula (I), and N-oxides thereof, and pharmaceutically acceptable salts thereof, and solvates and hydrates thereof, wherein R1, R2, R3, R4, R5, R6, Ra, x, y, L, G, Z, the bond denoted by “q”, the ring system denoted by “A” and the ring system denoted by “B” are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORy activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORy activity, for example, autoimmune and/or inflammatory disorders.
    Type: Application
    Filed: October 17, 2013
    Publication date: September 24, 2015
    Inventors: Wei Xu, Yong Wang, Sunghoon Ma, Elena S. Koltun, Byung Gyu Kim, Joon Won Jeong, T.G. Muralii Dhar, Lynn Canne Bannen
  • Acetanilide sphingosine-1-phosphate receptor antagonists
    Patent number: 8791102
    Abstract: This disclosure relates to sphingosine-1-phosphate (S1P) receptor antagonists, compositions comprising the S1P receptor antagonists and methods for using and processes for making the S1P receptor antagonists. In particular, this disclosure relates to sphingosine-1-phosphate 1 (S1P1) receptor antagonists, compositions comprising the S1P1 receptor antagonist and methods for using the S1P1 receptor antagonist, such as in the treatment of cancer, and processes for making the S1P1 receptor antagonists.
    Type: Grant
    Filed: October 16, 2009
    Date of Patent: July 29, 2014
    Assignee: Exelixis, Inc.
    Inventors: Mohamed Abdulkader Ibrahim, Joon Won Jeong, Henry William Beecroft Johnson, Patrick Kearney, James W. Leahy, Gary L. Lewis, Robin Tammie Noguchi, John M. Nuss
  • Sphingosine-1-Phosphate Receptor Antagonists
    Publication number: 20110288076
    Abstract: This disclosure relates to sphingosine-1-phosphate (S1P) receptor antagonists, compositions comprising the S1P receptor antagonists and methods for using and processes for making the S1P receptor antagonists. In particularly, this disclosure relates to sphingosine-1-phosphate 1 (S1P1) receptor antagonists, compositions comprising the S1P1 receptor antagonist and methods for using the S1P1 receptor antagonist, such as in the treatment of cancer, and processes for making the S1P1 receptor antagonists.
    Type: Application
    Filed: October 16, 2009
    Publication date: November 24, 2011
    Applicant: EXELIXIS, INC.
    Inventors: Mohamed Abdulkader Ibrahim, Joon Won Jeong, Henry William Beecroft Johnson, Patrick Kearney, James W. Leahy, Gary L. Lewis, Robin Tammie Noguchi, John M. Nuss
  • CDK Modulators
    Publication number: 20110201599
    Abstract: A compound according to Formula I: or a pharmaceutically-acceptable salt thereof, wherein R1, R3, A, B and D are as defined in the specification; pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: July 2, 2009
    Publication date: August 18, 2011
    Applicant: EXELIXIS, INC.
    Inventors: Suleyman Bahceci, Bryan Chan, Diva Sze-Ming Chan, Jeff Chen, Timothy Patrick Forsyth, Maurizio Franzini, Vasu Jammalamadaka, Joon Won Jeong, Lisa Renee Jones, Ryan Michael Kelley, Moon Hwan Kim, James W. Leahy, Morrison B. Mac, Robin Tammie Noguchi, Pallavi Rao, Brian Hugh Ridgway, Wei Xu, Yong Wang